alzheon, Author at Alzheon | Preserving Future Memories

About alzheon

This author has not yet filled in any details.
So far alzheon has created 204 blog entries.

18 Mar, 2025

Alzheon to Present Results from Pivotal APOLLOE4 Phase 3 Trial of Oral Valiltramiprosate/ALZ-801 at Dedicated Symposium at ADPD Conference in Vienna on April 1st, 2025

alzheon2025-03-14T11:11:08-04:00March 18th, 2025|

25 Feb, 2025

Alzheon Announces Two New Scientific Papers Ahead of APOLLOE4 Phase 3 Trial Topline Symposium at ADPD Conference in Vienna on April 1st, Marking 15 Pathbreaking Peer-Reviewed Publications from Alzheon

alzheon2025-02-23T13:49:33-05:00February 25th, 2025|

7 Jan, 2025

Alzheon Announces Appointment of Renowned Investor and Financial Executive Muneer A. Satter to Board of Directors

alzheon2025-01-03T09:31:33-05:00January 7th, 2025|

2 Jan, 2025

Could a single pill crack the code of treating Alzheimer’s disease?

alzheon2025-01-04T15:43:38-05:00January 2nd, 2025|

18 Sep, 2024

New Peer-Reviewed Scientific Publication Describes Study Design and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in APOE4/4 Homozygous Individuals with Early Alzheimer’s Disease

alzheon2025-02-20T18:54:55-05:00September 18th, 2024|

23 Jul, 2024

Alzheon to Present Phase 2 Biomarker Trial Results and Baseline Characteristics from APOLLOE4 Phase 3 Trial of Oral ALZ-801/Valiltramiprosate in Patients with Early Alzheimer’s Disease at Alzheimer’s Association International Conference

alzheon2024-07-19T10:15:31-04:00July 23rd, 2024|

25 Jun, 2024

Two Peer-Reviewed Scientific Publications Describe Fluid Biomarker, Brain Preservation and Clinical Benefits Following 2 Years of Treatment in Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease

alzheon2024-08-26T11:05:55-04:00June 25th, 2024|

24 Jun, 2024

Alzheon nabs $100M in series E to advance oral Alzheimer’s drug

alzheon2024-06-26T15:07:42-04:00June 24th, 2024|Tags: BioWorld|

20 Jun, 2024

Analysis of Cerebrospinal Fluid, Plasma β-Amyloid Biomarkers, and Cognition from a 2-Year Phase 2 Trial Evaluating Oral ALZ-801/Valiltramiprosate in APOE4 Carriers with Early Alzheimer’s Disease Using Quantitative Systems Pharmacology Model

alzheon2024-06-20T17:34:11-04:00June 20th, 2024|

20 Jun, 2024

Effects of Oral ALZ-801/Valiltramiprosate on Plasma Biomarkers, Brain Hippocampal Volume, and Cognition: Results of 2-Year Single-Arm, Open-Label, Phase 2 Trial in APOE4 Carriers with Early Alzheimer’s Disease

alzheon2024-06-20T17:34:20-04:00June 20th, 2024|